Tianzhou Ma

No ORCID on file · 22 papers in corpus · active 2014-2023

Study types

  • preprint 18
  • article 4

Condition tags

  • endometriosis 22
preprint 2023
·doi:10.1158/1078-0432.c.6522953

AbstractPurpose: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian …

preprint 2023
·doi:10.1158/1078-0432.c.6522953.v1

AbstractPurpose: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian …

preprint 2023
·doi:10.1158/1078-0432.22455170.v1

Supplementary Materials and Methods

preprint 2023
·doi:10.1158/1078-0432.22455170

Supplementary Materials and Methods

preprint 2023
·doi:10.1158/1078-0432.22455191.v1

Suppl Fig S1. Venn diagram of DE genes from 3 group comparisons

preprint 2023
·doi:10.1158/1078-0432.22455191

Suppl Fig S1. Venn diagram of DE genes from 3 group comparisons

preprint 2023
·doi:10.1158/1078-0432.22455188

Suppl Fig S2. Kras and Pten pathways in relationship to complement gene expression

preprint 2023
·doi:10.1158/1078-0432.22455188.v1

Suppl Fig S2. Kras and Pten pathways in relationship to complement gene expression

preprint 2023
·doi:10.1158/1078-0432.22455185

Suppl Fig S3. Antibody-mediated, complement-induced cytotoxicity

preprint 2023
·doi:10.1158/1078-0432.22455185.v1

Suppl Fig S3. Antibody-mediated, complement-induced cytotoxicity

preprint 2023
·doi:10.1158/1078-0432.22455182.v1

Suppl Fig S4. Complement and non-target siRNA

preprint 2023
·doi:10.1158/1078-0432.22455182

Suppl Fig S4. Complement and non-target siRNA

preprint 2023
·doi:10.1158/1078-0432.22455179.v1

Suppl Table S1. Differentially expressed genes from different group comparisons

preprint 2023
·doi:10.1158/1078-0432.22455179

Suppl Table S1. Differentially expressed genes from different group comparisons

preprint 2023
·doi:10.1158/1078-0432.22455176

Suppl Table S2. Top five canonical pathways from different group comparisons, identified via Ingenuity Pathway Analyses

preprint 2023
·doi:10.1158/1078-0432.22455176.v1

Suppl Table S2. Top five canonical pathways from different group comparisons, identified via Ingenuity Pathway Analyses

preprint 2023
·doi:10.1158/1078-0432.22455173.v1

Suppl Table S3. Top five networks from different group comparisons, identified via Ingenuity Pathway Analyses

preprint 2023
·doi:10.1158/1078-0432.22455173

Suppl Table S3. Top five networks from different group comparisons, identified via Ingenuity Pathway Analyses

article 2018
·doi:10.1158/1557-3265.ovca17-b23

Abstract Objectives: To investigate changes in estrogen receptor–alpha (ERα) signaling during the progression of endometriosis to endometriosis-associated ovarian cancer (EAOC) as a putative driver of malignant transformation. Methods: We p…

article 2018
Hormones & cancer ·doi:10.1007/s12672-018-0350-9
article 2016
·doi:10.1097/01.aog.0000483623.30686.73

INTRODUCTION: The goal of this project is to describe the development and implementation of an evidence-based hysterectomy clinical pathway to reduce unnecessary variations in care and to promote improved patient outcomes at a reduced cost.…

article 2014
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-14-1338

PURPOSE: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian tumors p…